Edition:
United Kingdom

La Jolla Pharmaceutical Co (LJPC.OQ)

LJPC.OQ on NASDAQ Stock Exchange Capital Market

23.91USD
8:59pm GMT
Change (% chg)

$-0.38 (-1.56%)
Prev Close
$24.29
Open
$24.31
Day's High
$24.65
Day's Low
$22.68
Volume
332,349
Avg. Vol
108,619
52-wk High
$39.26
52-wk Low
$16.43

Latest Key Developments (Source: Significant Developments)

La Jolla Pharma files for mixed shelf of up to $150 mln ‍​
Friday, 27 Oct 2017 

Oct 27 (Reuters) - La Jolla Pharmaceutical Co :Files for mixed shelf of up to $150 million - SEC filing‍​.  Full Article

La Jolla reports Q3 loss $1.19/shr
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - La Jolla Pharmaceutical Co :La Jolla Pharmaceutical Company announces financial results for the three and nine months ended September 30, 2017 and recent corporate progress.Q3 loss per share $1.19.Q3 earnings per share view $-1.24 -- Thomson Reuters I/B/E/S.La Jolla Pharmaceutical-‍as of Sept 30, 2017, co had $120.8 million in cash,cash equivalents, versus $65.7 million of cash and cash equivalents at Dec 31, 2016​.  Full Article

Prudential Financial reports 10.1 pct passive stake ​in La Jolla Pharmaceutical
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - La Jolla Pharmaceutical Co ::Prudential Financial Inc reports 10.1 percent passive stake ​in La Jolla Pharmaceutical Co as of Sept 30 - sec filing ‍.  Full Article

La Jolla Pharmaceutical Company announces financial results for the three and six months ended June 30, 2016
Monday, 8 Aug 2016 

La Jolla Pharmaceutical Co : La Jolla Pharmaceutical Company announces financial results for the three and six months ended June 30, 2016 . Quarterly loss per share $0.90 .Q2 earnings per share view $-0.99 -- Thomson Reuters I/B/E/S.  Full Article

La jolla Pharmaceutical Co reports Q1 loss per share of $0.96
Friday, 6 May 2016 

La Jolla Pharmaceutical Co : La jolla pharmaceutical company announces first quarter 2016 financial results and recent corporate progress . Q1 loss per share $0.96 . Q1 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S .Qtrly total revenue $234,000.  Full Article

BRIEF-La Jolla Pharmaceutical Co Announces Initiation Of Clinical Study Of LJPC‑401 In Patients With Beta Thalassemia

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES INITIATION OF PIVOTAL CLINICAL STUDY OF LJPC-401 IN PATIENTS WITH BETA THALASSEMIA Source text for Eikon: Further company coverage: